Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors

Aggressive pituitary tumors are rare but difficult to manage, as there is no effective chemotherapy to restrict their growth and cause their shrinkage. Within these tumors, growth-promoting cascades, like the PI3K/mTOR pathway, appear to be activated. We tested the efficacy of two inhibitors of this pathway, NVP-BKM120 (Buparlisib; pan-PI3K) and NVP-BEZ235 (dual PI3K/mTOR), both in vitro on immortalized pituitary tumor cells (GH3) and on primary cell cultures of human pituitary tumors and in vivo on a rat model of prolactin (PRL) tumors (SMtTW3). In vitro, NVP-BEZ235 had a potent apoptotic and cytostatic effect that was characterized by decreased cyclin D/E and Cdk4/2 protein levels and subsequent accumulation of cells in G1. In vivo, the effect was transient, with a decrease in mitotic index and increase in apoptosis; long-term treatment had no significant inhibitory effect on tumor growth. In contrast, while NVP-BKM120 had little effect in vitro, it dramatically limited tumor growth in vivo. Increased Akt phosphorylation observed only in the NVP-BEZ235–treated tumors may explain the differential response to the two inhibitors. Primary cell cultures of human PRL pituitary tumors responded to NVP-BEZ235 with reduced cell viability and decreased hormone secretion, whereas NVP-BKM120 had little effect. Altogether, these results show a potential for PI3K inhibitors in the management of aggressive pituitary tumors. Mol Cancer Ther; 15(6); 1261–70. ©2016 AACR.

[1]  G. Johannsson,et al.  Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. , 2015, The Journal of clinical endocrinology and metabolism.

[2]  T. Tateno,et al.  The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. , 2014, Endocrine-related cancer.

[3]  Antonio Di Ieva,et al.  Aggressive pituitary adenomas—diagnosis and emerging treatments , 2014, Nature Reviews Endocrinology.

[4]  D. Maiter,et al.  Therapy of endocrine disease: the challenges in managing giant prolactinomas. , 2014, European journal of endocrinology.

[5]  J. Trouillas.  In Search of a Prognostic Classification of Endocrine Pituitary Tumors , 2014, Endocrine Pathology.

[6]  E. Jouanneau,et al.  Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. , 2014, European journal of endocrinology.

[7]  D. Heymann,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. , 2014, Cancer letters.

[8]  F. Rea,et al.  mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. , 2013, Endocrine-related cancer.

[9]  D. Figarella-Branger,et al.  A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up , 2013, Acta Neuropathologica.

[10]  B. Xing,et al.  Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. , 2013, Endocrinology.

[11]  J. Pickard,et al.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature , 2012, Pituitary.

[12]  D. Figarella-Branger,et al.  Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment , 2012, Clinical endocrinology.

[13]  D. Dworakowska,et al.  Temozolomide in the management of dopamine agonist–resistant prolactinomas , 2012, Clinical endocrinology.

[14]  F. Ducray,et al.  New targeted therapies in pituitary carcinoma resistant to temozolomide , 2012, Pituitary.

[15]  M. Varrin-doyer,et al.  Human T Lymphotropic Virus Type 1 Increases T Lymphocyte Migration by Recruiting the Cytoskeleton Organizer CRMP2 , 2012, The Journal of Immunology.

[16]  W. Sellers,et al.  Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.

[17]  A. Grossman,et al.  Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status , 2011, European journal of clinical investigation.

[18]  R. Hales,et al.  Nelfinavir induces radiation sensitization in pituitary adenoma cells , 2011, Cancer biology & therapy.

[19]  N. Demartines,et al.  Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib , 2011, Molecular Cancer.

[20]  N. Pellegata,et al.  Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition , 2011, Molecular Cancer Therapeutics.

[21]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[22]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[23]  K. M. Chen,et al.  Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma , 2011, Clinical Cancer Research.

[24]  M. Reni,et al.  Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. , 2010, European journal of endocrinology.

[25]  E. Laws,et al.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. , 2010, The Journal of clinical endocrinology and metabolism.

[26]  S. Brand,et al.  Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. , 2010, Cancer letters.

[27]  J. Lachuer,et al.  Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. , 2010, The Journal of clinical endocrinology and metabolism.

[28]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Zatelli,et al.  Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. , 2010, The Journal of clinical endocrinology and metabolism.

[30]  M. Buchfelder,et al.  The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. , 2010, Cancer research.

[31]  M. Korbonits,et al.  Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. , 2009, Endocrine-related cancer.

[32]  I. Shimon,et al.  Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. , 2009, Endocrine-related cancer.

[33]  J. Olson,et al.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.

[34]  H. Lane,et al.  Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition , 2009, Molecular Cancer Therapeutics.

[35]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[36]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[37]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[38]  J. Lachuer,et al.  A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. , 2007, Endocrine-related cancer.

[39]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[40]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[41]  Robert T. Abraham,et al.  Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.

[42]  M. Korbonits,et al.  Enhanced protein kinase B/Akt signalling in pituitary tumours. , 2005, Endocrine-related cancer.

[43]  M. Buchfelder,et al.  Diagnosis and Management of Pituitary Carcinomas , 2005 .

[44]  James M. Roberts,et al.  Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.

[45]  M. Low,et al.  Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Claustrat,et al.  Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma. , 1990, Cancer research.

[47]  U. Renner,et al.  Cellular and molecular specificity of pituitary gland physiology. , 2012, Physiological reviews.

[48]  M. Buchfelder,et al.  Clinical review: Diagnosis and management of pituitary carcinomas. , 2005, The Journal of clinical endocrinology and metabolism.

[49]  S. Melmed,et al.  Pathophysiology of pituitary adenomas. , 2005, Journal of endocrinological investigation.

[50]  E. Hooghe-Peters,et al.  Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression. , 1999, Endocrinology.

[51]  E. Hooghe-Peters,et al.  Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. , 1994, Endocrinology.